Switching to, then stopping treatment with nilotinib for CML patients.

• Research type

  Research Study

• Full title

  A prospective, randomized, open label, two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia positive CML after two different durations of consolidation treatment with nilotinib 300mg BID.

• IRAS ID

  146148

• Contact name

  Jane Apperley

• Contact email

  j.apperley@imperial.ac.uk

• Sponsor organisation

  Novartis Pharma Services AG

• Eudract number

  2012-005124-15

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  14/LO/0521

• Date of REC Opinion

  23 May 2014

• REC opinion

  Further Information Favourable Opinion